Skip to main content
. 2023 Jan 10;13:1049289. doi: 10.3389/fphar.2022.1049289

TABLE 2.

Patient Characteristics.

Control Group (n = 86) Intervention Group (n = 82) p
Sex n, (%) >0.05
 Female 28, (32.56%) 43, (52.44%)
 Male 58, (67.44%) 39, (47.56%)
BMI (Median [IQR]) 25.95, [23.43–28.07] 25.20, [23.40–27.70] >0.05
Weight (kg) 75, [70–80] 71, [65–80]
Height (m) 1.7, [1.66–1.74] 1.67, [1.6–1.75]
Age (mean ± SD) 72.19 ± 12.73 68.80 ± 16.30 >0.05
No of Comorbidities (mean ± SD) 3.71 ± 1.74 3.66 ± 1.67 >0.05
 1 (n, %) 6, (6.98%) 9, (10.97%)
 2 (n, %) 18, (20.93%) 14, (17.07%)
 3 (n, %) 22, (25.58%) 16, (19.51%)
 4 (n, %) 11, (12.79%) 17, (20.73%)
 5 (n, %) 16, (18.60%) 12, (14.63%)
 6 (n, %) 6, (6.98%) 11, (13.41%)
 7 (n, %) 5, (5.81%) 3, (3.65%)
 8 (n, %) 2, (2.33%)
Most common 10 Comorbidities (n, %) N.A.
 Hypertension 42, (48.84%) 49, (59.75%)
 Coronary Artery Disease 35, (40.70%) 27, (32.93%)
 Chronic obstructive pulmonary disease 31, (36.05%) 32, (39.02%)
 Type 2 Diabetes Mellitus 27, (31.40%) 21, (25.61%)
 Pulmonary Embolism 24, (27.91%) 13, (15.85%)
 Cancer 22, (25.58%) 14, (17.07%)
 Asthma 12, (13.95%) 11, (13.41%)
 Atrial Fibrillation 12, (13.95%) 4, (7.87%)
 Kidney failure 12, (13.95%) 14, (17.07%)
Length of Hospital Stay (day) (mean ± SD) 11.57 ± 8.56 9.72 ± 6.08 p > 0.05
 <10 (n, %) 44, (51.16%) 51, (62.20%)
 10-19 (n, %) 28, (32.56%) 26, (31.71%)
 20-30 (n, %) 9, (10.46%) 4, (4.88%)
 >30 (n, %) 5, (5.82%) 1, (1.12%)
Number of Drugs per patient (mean ± SD) 14.45 ± 7.59 15.5 ± 6.18 p > 0.05
Charlson Comorbidity Index (CCI) (Median, [IQR]) 5, [3–7] 4, [3–6] p > 0.05